CAESAR's legacy: a new era of rigor in preclinical studies of cardioprotection
- PMID: 34018051
- PMCID: PMC8137617
- DOI: 10.1007/s00395-021-00874-8
CAESAR's legacy: a new era of rigor in preclinical studies of cardioprotection
Comment on
-
Preclinical trial of a MAP4K4 inhibitor to reduce infarct size in the pig: does cardioprotection in human stem cell-derived myocytes predict success in large mammals?Basic Res Cardiol. 2021 May 20;116(1):34. doi: 10.1007/s00395-021-00875-7. Basic Res Cardiol. 2021. PMID: 34018053 Free PMC article.
References
-
- Bøtker HE, Hausenloy D, Andreadou I, Antonucci S, Boengler K, Davidson SM, Deshwal S, Devaux Y, Di Lisa F, Di Sante M, Efentakis P, Femminò S, García-Dorado D, Giricz Z, Ibanez B, Iliodromitis E, Kaludercic N, Kleinbongard P, Neuhäuser M, Ovize M, Pagliaro P, Rahbek-Schmidt M, Ruiz-Meana M, Schlüter KD, Schulz R, Skyschally A, Wilder C, Yellon DM, Ferdinandy P, Heusch G. Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res Cardiol. 2018;113:39. doi: 10.1007/s00395-018-0696-8. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
